307750 — Kukjeon Pharmaceutical Co Balance Sheet
0.000.00%
- KR₩175bn
- KR₩196bn
- KR₩136bn
Annual balance sheet for Kukjeon Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 9,959 | 39,259 | 94,971 | 64,833 | 46,824 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 16,299 | 20,409 | 23,919 | 29,101 | 29,475 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 39,004 | 76,915 | 142,893 | 123,992 | 105,189 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 14,473 | 24,026 | 46,118 | 86,060 | 87,360 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 57,802 | 106,989 | 196,097 | 225,102 | 212,273 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 21,782 | 21,852 | 70,691 | 99,823 | 88,576 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 25,572 | 23,838 | 104,500 | 128,681 | 114,853 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Total Equity | 32,230 | 83,150 | 91,597 | 96,422 | 97,420 |
| Total Liabilities & Shareholders' Equity | 57,802 | 106,989 | 196,097 | 225,102 | 212,273 |
| Total Common Shares Outstanding |